EUCTR2006-001907-13-ES进行中（未招募）1 期
etrozol frente a Letrozol más Lapatinib (GW572016) en cáncer de mama hormosensible y operable, con HER-2 negativo. Estudio en Fase II aleatorizado y doble ciego con evaluación de biomarcadores. (Letrozole versus Letrozole plus lapatinib (GW572016) in hormone-sensitive, HER-2 negative operable breast cancer. A double blind randomized phase II study with biomarker evaluation) - LETLOB
GlaxoSmithKline Research and Development Limited0 个研究点目标入组 0 人开始时间: 2007年7月2日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Histologically confirmed infiltrating primary breast cancer of > 2.0 cm in size in largest clinical diameter; ER and/or PgR positive cancer (> 10% of positive cancer cell assessed by IHC); postmenopausal status; HER2 negative tumors (IHC 0-2+, or FISH negative); availability of tumor tissue suitable for biological and molecular examination before starting primary treatment; age over 18; ECOG PS 0-1; normal organ and marrow function; cardiac ejection fraction within the institutional range of normal as measured by echocardiogram or MUGA scan; ability to understand and the willingness to sign a written informed consent document; ability to swallow and retain oral medication.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Stage IIIB, IIIC and inflammatory breast cancer; Stage IV breast cancer; contraindication to the treament with letrozole; prior treatment with chemotherapy, endocrine therapy and radiotherapy. Prior treatment with EGF targeting therapies; Treatment with any other investigational agents, or with all herbal (alternative) medicines; history of allergic reactions attributed to compounds of similar chemical or biological composition to lapatinib; uncontrolled inter-current illnesses; HIV-positive patients receiving combination anti-retroviral therapy; GI tract disease resulting in the inability to take oral medication; concomitant requirement for medication classified as CYP3A4 inducers or inhibitors
研究者
相似试验
进行中（未招募）
不适用
ETROZOLE versus LETROZOLE PLUS LAPATINIB GW572016 IN HORMONE-SENSITIVE, HER-2 NEGATIVE OPERABLE BREAST CANCER. A DOUBLE BLIND RANDOMIZED PHASE II STUDY WITH BIOMARKER EVALUATION - LAP107692 - LETLOBPrimary breast cancer hormone-sensitive in postmenopausal womenMedDRA version: 6.1Level: PTClassification code 10057654EUCTR2006-001907-13-ITGLAXO SMITH KLINE RESEARCH DEVELOPMENT LTD91
进行中（未招募）
1 期
etrozole versus Letrozole plus lapatinib (GW572016) in hormone-sensitive, HER-2 negative operable breast cancer. A double blind randomized phase II study with biomarker evaluation - LETLOBEUCTR2006-001907-13-GBGlaxoSmithKline Research and Development Limited
招募中
2 期
etrozole for IUIIRCT20220412054511N1Shahid Beheshti University of Medical Sciences80
已完成
2 期
Comparison investigation of the effect of Letrozole misoprostol to induce abortion in the second trimester of pregnancyTermination of pregnancy in the second trimester.Medical abortionIRCT2015123114333N48Vice chancellor for research, Kermanshah University of Medical Sciences120
尚未招募
不适用
Adding Letrozole to antagonist protocol in second ICSI attemptFertility-femaleWomen scheduled to second trial ICSIPACTR201308000582203Prof Dr Hassa Aly Hassan Elmaghraby330